Clinical Trial Update: A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL) [Phase 3]

View source ↗

Summary

A Phase III study is evaluating JS004 plus toripalimab versus investigator-selected chemotherapy in patients with PD-(L)1 monoclonal antibody refractory classic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classic Hodgkin Lymphoma

Drugs mentioned

• JS004 (JS004)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Hodgkin Lymphoma | Phase 3 | Status: RECRUITING